Inclusion Criteria:

          -  Patients with histologically/cytologically confirmed advanced solid tumors with FGFR1
             or FGFR2 amplification or FGFR3 mutation, for which no further effective standard
             anticancer treatment exists

          -  Adequate bone marrow function

          -  Adequate hepatic and renal function

          -  Adequate cardiovascular function

          -  Contraception.

               -  For women: Must be surgically sterile, post-menopausal, or compliant with a
                  medically approved contraceptive regimen during and for 3 months after the
                  treatment period; must have a negative serum or urine pregnancy test and must not
                  be nursing.

               -  For men: Must be surgically sterile or compliant with a contraceptive regimen
                  during and for 3 months after the treatment period

        Exclusion Criteria:

          -  Patients with primary CNS tumor or CNS tumor involvement

          -  Patients with history and/or current evidence of endocrine alteration of
             calcium-phosphate homeostasis

          -  History and/or current evidence of ectopic mineralization/ calcification including but
             not limited to the soft tissue, kidneys, intestine, myocard and lung with the
             exception of calcified lymphnodes and asymptomatic coronary calcification

          -  Current evidence of corneal disorder/ keratopathy incl. but not limited to bullous/
             band keratopathy, corneal abrasion, inflammation/ulceration, keratoconjunctivitis
             etc., confirmed by ophthalmologic examination.

          -  History or current evidence of cardiac arrhythmia and/or conduction abnormality

          -  Women who are pregnant or nursing.

        Other protocol-defined inclusion/exclusion criteria may apply